KNOWLEDGE BANK

Interviews

MAb Aggregation: A Problem Within the Biopharmaceutical Industry

Associate Professor, Trinity College Dublin, Ireland
Educated at Seoul National University UC Berkeley and Purdue University with postdoctoral research at the University of Oxford KH Mok specializes in utilising biomolecular NMR spectroscopy to protein foldingmisfoldingaggregation research Coauthor of publications in Nature Nature Communications Nature Immunology PNAS and others he currently serves as a Eureka Independent Evaluation Panel member tec...

Articles

Harnessing Artificial Intelligence

The incorporation of Artificial Intelligence AI in the discovery and development of drugs represents a significant step towards transforming drug delivery systems

Research Insights

The Properties of Human Disease Mutations at Protein Interfaces

The assembly of proteins into complexes and their interactions with other biomolecules are often vital for their biological function While it is known that mutations at protein interfaces have a high potential to be damaging and cause human genetic disease there has been relatively

Techno Trends

Regeneron Pharmaceuticals Introduced Dupixent® First and Only Treatment for Children with Eosinophilic Oesophagitis (EoE)

Regeneron Pharmaceuticals has introduced Dupixent for treating paediatric patients aged to years with eosinophilic oesophagitis weighing at least kg Dupixent a fully human monoclonal antibody

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Perspectives on the Vaccine Industry

Josephine Cheng

As a Senior Consultant in Bioprocessing Strategy at Merck with over 14 years of
international biopharma experience, Josephine Cheng focuses on vaccine and mRNA market segments, where she translates strategies into market initiatives to enable the utilisation of best-in-class technologies and transforms industry insights into sustainable business strategies.
Josephine obtained Bachelor's and Master's degrees in Bio-resource's; Agriculture from the National Taiwan University.

 

2

The Past, Present, and Future of Sickle-cell Disease Registries: Findings from a Global Review

Samuel Llewellyn

Sam is an Associate Director in Patient-Centered Research at Vitaccess, providing direction and oversight across their health economics and outcomes research, patient-centered outcomes, and real-world evidence portfolio. Sam joined Vitaccess in 2018, after spending three years as a project manager within the PCO group at a leading contract research organisation.

 

Fatemeh Amini

Fatemeh is a Medical Writer at Vitaccess. She plays a key role in their digital real-world evidence studies, developing materials that range from client-facing deliverables through to content communicating the value and progress of studies to clinical experts, patient representatives, and participants.

 

Oktawia Borecka

Oktawia is a Research Associate at Vitaccess, contributing to their patient-reported outcomes and clinical outcome assessment projects and supporting the development, effective delivery, and quality of their real-world studies. Oktawia has experience in health research from previous roles involving healthcare technologies, a medical ventures accelerator, and her doctoral research studies.

 

Akosua Ofori

Akosua is an Associate Consultant at Vitaccess, currently project managing a range of their longitudinal and cross-sectional real-world evidence studies. She has experience in developing evidence-generation strategies for clients, including gap analyses for health technology assessment submissions and the reimbursement of digital health technologies.

 

3

Viksit Bharat@ 2047 envisioned the Indian Pharma Industry

Md. Faiyazuddin

Professor Md. Faiyazuddin, a distinguished academician with extensive experience working across the government, public and private sectors, sought to leverage his sixteen-year background in pharmacy education, product development, research consultation, and social pharmacy outreach activities in academia and industry. He is a Senior Professor and former Dean, R&D, Al-Karim University, who is lecturing on health and drug delivery research and holds visiting positions at prestigious universities in India and abroad. He has successfully completed research grants from various R&D agencies, such as SERB-DST and foreign agencies (DSR-UoH, DST, UiTM, Malaysia, Sick’s Children Hospital, Canada) worth Rs. 1.12 Million INR. With more than 120 research, conference, and review manuscripts, dozens of books and chapters, 15 accolades and awards, and various IPR have contributed greatly to the pharm fraternity of India. In addition to his daily job, Dr. Faiyazuddin has a keen interest in connecting researchers worldwide for practicing safe drugs under the flagship of the International Pharmaceutical Forum (a community of more than 250 pharma stalwarts across the globe).

 

Yogesh Subhash Chaudhari

Yogesh Subhash Chaudhari, a passionate educator at Dr L H Hiranandani College of Pharmacy, has contributed significantly to this field through research and review of papers in prestigious journals. His insights on AI for Pharmacist Newsletters on Linkedin are as follows.

 

4

Reshaping the Clinical Trial Model

Anna Hayes

Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.

5

A BITTER PILL: Exploring the Realm of Drug Counterfeiting

Stephen Ward

Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

Angelo Krizmanic

Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

press releasesRead more...

Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company

Lonza the worlds leading contract development and manufacturing organization CDMO today announced an expanded strategic collaboration with a leading USbased biopharmaceutical company

Cartherics recognised as Asia Pacific Emerging Leader in Allogeneic Cell Therapy

Cartherics Pty Ltd Cartherics or Company a biotechnology company developing offtheshelf immune cell therapies focusing on highimpact womens diseases with lead programs in ovarian cancer and endometriosis

Icosagen completes €45 million expansion, bringing therapeutic protein discovery, development and GMP manufacturing together under one roof

Estoniabased biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and manufacturing capabilities at a single site creating a seamless pathway

AGC Biologics Expands to Fill-Finish in U.S. Through Strategic Partnership with Pyramid Pharma Services

Drug developers have a new optimized option for USbased manufacturing as AGC Biologics enters a strategic partnership with Pyramid Pharma Services The collaboration combines AGC Biologics expertise

Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases

VectHorus a privately held biotechnology company that designs and develops molecular vectors facilitating the targeted delivery of therapeutic molecules and imaging agents announces a research evaluation and exclusive

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

Roche announced today that the US Food and Drug Administration FDA has accepted and granted priority review to a supplemental Biologics License Application sBLA for Enspryng satralizumab

EventsRead more...

07 - 09

Jul 2026

The Pharma India Expo 2026

Bombay Exhibition Centre, Mumb...

07 - 09

Jul 2026

08 - 10

Jul 2026

CPHI SEA 2026

QSNCC, Bangkok, Thailand

09 - 11

Jul 2026

Pharma Pro&Pack Expo 2026

HITEX Exhibition Centre, Hyder...

16 - 19

Jul 2026

Bio Asia Taiwan 2026

Taipei Nangang Exhibition Cent...

20 - 22

Jul 2026

6th mRNA-Based Therapeutics Summit

The Westin Boston Seaport Dist...

20 - 22

Jul 2026

24 - 25

Jul 2026

LATEST NEWSRead more...

Viva Biotech and Adjutor Group Partner to Expand Global Drug Development Services

Viva Biotech and Adjutor Group have announced a collaboration aimed at expanding their international business networks and strengthening engagement with global life sciences partners

Excalipoint Therapeutics partners with Roche to evaluate EXP011 in DLL3-expressing solid tumours

Excalipoint Therapeutics has entered into a clinical trial collaboration with Roche to evaluate its lead product candidate EXP CTM in combination with atezolizumab for the treatment of DLLexpressing solid tumours

Innovent Biologics and Lilly sign commercialisation agreement for Verzenios in mainland China

Innovent Biologics and Eli Lilly and Company have signed a distribution and promotion agreement for Verzenios abemaciclib in mainland China

Roche launches AXELIOS 1 next-generation sequencing platform

Roche has launched AXELIOS its nextgeneration sequencing platform powered by proprietary Sequencing by Expansion SBX technology The new system combines high accuracy rapid sequencing flexibility

Ipsen to acquire Kartos Therapeutics, expanding late-stage haemato-oncology pipeline

Ipsen has entered into a definitive merger agreement to acquire Kartos Therapeutics strengthening its latestage haematooncology pipeline The acquisition adds navtemadlin an investigational MDM inhibitor

Ionis Licenses Zilganersen Rights Outside US to Recordati

Ionis Pharmaceuticals has signed a licensing agreement with Recordati granting the company exclusive rights to develop and commercialise the investigational medicine zilganersen for Alexander disease AxD